WaveMan · Company
APMD · Apnimed, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

APMD Apnimed (APMD) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001745648
Quote by TradingView
SEC filings
Insider net, 180 days
$5.2M
Buys minus sells, Form 4 codes P and S
Insider buyers, 180 days
2
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
0
13F, latest reported quarter
Revenue growth
-29.4%
XBRL, annual
Net margin
1042.5%
Conversions, 180 days
6
Codes C/M, not in net · $20.4M priced
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
History
none filed
Jun 2026$12.1M
Mar 2026n/a
Jun 2025$17.1M
Mar 2025n/a
At each fiscal year end
Single quarter
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
History
none filed
Jun 2026+1,043%
Mar 2026n/a
Jun 2025-406.0%
Mar 2025n/a
At each fiscal year end
Single quarter
Free cash flow, TTM
n/a
fewer than four consecutive quarters of operating cash flow
History
none filed
Jun 2026n/a
Mar 2026n/a
Jun 2025n/a
Mar 2025n/a
At each fiscal year end
Single quarter
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
History
none filed
Jun 2026n/a
Mar 2026n/a
Jun 2025n/a
Mar 2025n/a
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
needs four quarters of operating cash flow
History
none filed
Jun 2026n/a
Mar 2026n/a
Jun 2025n/a
Mar 2025n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
fewer than four consecutive quarters of net income
History
none filed
Jun 2026n/a
Mar 2026n/a
Jun 2025n/a
Mar 2025n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
n/a
fewer than four consecutive quarters of net income
History
none filed
Jun 2026n/a
Mar 2026n/a
Jun 2025n/a
Mar 2025n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
History
none filed
Jun 2026n/a
Mar 2026n/a
Jun 2025n/a
Mar 2025n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
History
none filed
Jun 2026n/a
Mar 2026n/a
Jun 2025n/a
Mar 2025n/a
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
History
none filed
Jun 2026n/a
Mar 2026n/a
Jun 2025n/a
Mar 2025n/a
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$638.5M
market value at close 2026-10-09 on 2026-09-04 shares, plus long-term debt only, 2026-06-30, minus cash 2026-06-30
History
none filed
Jun 2026n/a
Mar 2026n/a
Jun 2025n/a
Mar 2025n/a
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
fewer than four consecutive quarters of operating cash flow
History
none filed
Jun 2026n/a
Mar 2026n/a
Jun 2025n/a
Mar 2025n/a
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
History
none filed
Jun 2026n/a
Mar 2026n/a
Jun 2025n/a
Mar 2025n/a
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-09. Hover a figure to see how it was computed.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.

APMD Stock Sonar score 4/7 axes

Find similar shapesCompare

APMD ranks highest on insider conviction (87th percentile) and risk and compliance (44th), and lowest on institutional and government (7th), among Pharma & Biotech peers.

Growth
28
Inputs
  • Revenue growth, YoY-29.4% · 28 pct, sector of 506
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
87
Inputs
  • Net open-market buying, 180d$5.2M · 94 pct, sector of 442
  • Insider buyers, 180d2 · 79 pct, sector of 449
Institutional and government
7
Inputs
  • Funds adding, latest quarterfewer than five funds report holding it
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quarters$40K · 7 pct, sector of 135
Risk and compliance
44
Inputs
  • Short interest, % of float+8.6% · 44 pct, sector of 814
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
3 not measured: Profitability, Financial health, US patents
  • Profitability needs 2 of 4 inputs, 0 present: fewer than four consecutive quarters of net income; fewer than four consecutive quarters of operating income
  • Financial health needs 1 of 2 inputs, 0 present: equity is zero or negative, the ratio has no meaning; needs four quarters of operating cash flow
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

What the filings say about APMD

In the 180 days to 2026-10-12, Apnimed insiders were net buyers of APMD, a net $5.2M across purchases and sales reported on Form 4 by 2 buyers. Most of that figure, $5.0M, came from a holder of 10% or more rather than an officer or director. 2 different insiders reported purchases within the last 90 days, a cluster buy, which is rarer than a single purchase. Each figure is counted from SEC and House filings as of 2026-10-12, dated the day the filing was made public.

APMD filings FAQ

Are Apnimed insiders buying or selling APMD?

In the 180 days to 2026-10-12, Apnimed insiders were net buyers, a net $5.2M across purchases and sales reported on Form 4, by 2 buyers.

Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$5.2M over 180 days
+$5.2M over 90 days · +$5.0M of it by a 10%+ holder
more than 94% of Pharma & Biotech
Congress
no Congress trades reported
Funds
under five funds report holding it
Revenue
-29.4% year over year (latest quarter)
below 72% of Pharma & Biotech
Margin
1042.5% net margin (latest quarter)
more than 99% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
8.6% of the float short (float per yahoo 2026-10-09) · 2.1 days to cover · settled 2026-09-30
below 53% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch APMD

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-25.9%12M
-28%-8%+11%+30%2026-072026-082026-082026-092026-092026-092026-10 2026-08-03 · Morningside Venture Investments Ltd bought $5.0M2026-08-03 · SEKHRI PAUL J bought $200.0K
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $5.2M bought by insiders over 180 days. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

Apnimed insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Apnimed, Inc. insiders bought a net $5.2M of stock across 2 Form 4 purchases and sales, with 2 insider(s) buying. Source: SEC Form 4 filings, as of 2026-10-12.

Insider
Filed
Shares
Value
SEKHRI PAUL J
Director
BUY
2026-08-03
12,500
$200.0K
Context
  • First open-market trade here by this insider on our record.
  • The trade is 100.0% of the 12,500 shares held after it.
  • 1 other insider bought within 30 days.
Insider activity: Director SEKHRI PAUL J bought about $200.0K of APMD on the open market on Aug 3, 2026, the largest insider purchase at the company on our record; 1 other insider bought within 30 days.
Morningside Venture Investments Ltd
BUY
2026-08-03
312,500
$5.0M
Context
  • First open-market trade here by this insider on our record.
  • The trade is 4.4% of the 7,152,713 shares held after it.
  • 1 other insider bought within 30 days.
Insider activity: Insider Morningside Venture Investments Ltd bought about $5.0M of APMD on the open market on Aug 3, 2026, the largest insider purchase at the company on our record; 1 other insider bought within 30 days.
2 transactions on record · a thin record, read with care
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to use the screener and CSV export. We store only your email; there is no password.

Who owns APMD: institutional holders (13F)

13F holdings, latest reported quarter
SEC 13F
No reported 13F holders

No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.

Congress trades in APMD

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

APMD planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Clinical pipeline
11 registered trials, 1 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
7
Phase 2
0 active
3
Phase 3
1 active
1
Multi-phase
0 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies